Tuberculose latente entre pessoas com hiv/aids

Josiane Maria Oliveira Souza, Tayse Tâmara Paixão Duarte, Sandra Renata Nakashoji, Michelle Zampieri Ipolito, Marcia Cristina Silva Magro

Resumo


RESUMO

Objetivo: buscar evidências sobre o uso da terapia preventiva com isoniazida na redução do risco da tuberculose ativa entre as pessoas vivendo com HIV/Aids mediante os resultados dos ensaios de liberação do interferon-gama (IGRA). Método: trata-se de estudo bibliográfico, descritivo, tipo revisão integrativa, com busca de artigos nas bases de dados publicados de 2010 a 2017. Os descritores utilizados foram HIV, AIDS, terapia preventiva com isoniazida, tratamento da infecção latente da tuberculose, interferon-gama, ensaios de liberação do interferon-gama. Resultados: selecionaram-se três artigos, com 1815 PVHA e desenvolvimento de tuberculose em apenas um caso, após 24 meses de terapia preventiva com isoniazida. Altas taxas de reversão e conversão durante o seguimento. Conclusão: consideraram-se os estudos abordando os benefícios da terapia preventiva com isoniazida a partir do resultado do IGRA apresentam-se escassos, com incipiente sugestão da limitação do teste seriado para o seguimento da resposta da terapia entre as PVHA. Além disso, destaca-se a necessidade de se investir em mais estudos que explorem a temática e superem as limitações já encontradas tendo em vista a alta relevância de se investir em novas estratégias que impactem o controle da coinfecção TB/HIV. Descritores: Tuberculose Latente; Teste Tuberculínico; Interferon-gama; HIV; Enfermagem; Prevenção de Doenças. 

ABSTRACT

Objective: to search for evidence on the use of isoniazid preventive therapy in reducing the risk of active tuberculosis among people living with HIV / AIDS through the results of interferon-gamma (IGRA) release trials. Method: a descriptive, descriptive, integrative review type, with search of articles in the databases published from 2010 to 2017. The descriptors used were HIV, AIDS, isoniazid preventive therapy, treatment of latent tuberculosis infection, interferon-gamma, of interferon-gamma release. Results: three articles were selected, with 1815 PLHA and tuberculosis development in only one case, after 24 months of preventive therapy with isoniazid. High rates of reversal and conversion during follow-up. Conclusion: studies addressing the benefits of preventive therapy with isoniazid from the IGRA result are scarce, with an incipient suggestion of limiting the serial test for the follow-up of the therapy response among PLHA. In addition, there is a need to invest in more studies that explore the issue and overcome the limitations already encountered in view of the high relevance of investing in new strategies that impact the control of TB / HIV co-infection. Descriptors: Latent Tuberculosis; Tuberculin Test; Interferon-gamma; HIV; Nursing; Prevention of Diseases. 

RESUMEN

Objetivo: buscar evidencias sobre el uso de la terapia preventiva con isoniazida en la reducción del riesgo de la tuberculosis activa entre las personas que viven con el VIH / SIDA, a través de los resultados de los ensayos de liberación del interferón gamma (IGRA). Método: estudio bibliográfico, descriptivo, tipo revisión integrativa, con búsqueda de artículos en las bases de datos publicados de 2010 a 2017. Los descriptores utilizados fueron: VIH, SIDA, terapia preventiva con isoniazida, tratamiento de la infección latente de la tuberculosis, interferón-gamma, ensayos de liberación del interferón-gamma. 0 se seleccionaron tres artículos, con 1815 PVHA y desarrollo de tuberculosis en apenas un caso, después de 24 meses de terapia preventiva con isoniazida. Altas tasas de reversión y conversión durante el seguimiento. Conclusión: los estudios abordando los beneficios de la terapia preventiva con isoniazida a partir del resultado del IGRA se presentan escasos, con incipiente sugerencia de la limitación de la prueba seriada para el seguimiento de la respuesta de la terapia, entre las PVHA. Además, se destaca la necesidad de invertir en más estudios que puedan explorar la temática y supere las limitaciones ya encontradas, visto la alta relevancia de invertir en nuevas estrategias que impacten en el control de la coinfección TB / VIH. Descritores: Tuberculosis Latente, Prueba de Tuberculina, Interferón Gamma; VIH, Enfermería; Prevención de Enfermedades.

Palavras-chave


Tuberculose Latente; Teste Tuberculínico; Interferon-gama; HIV; Enfermagem; Prevenção de doenças.

Texto completo:

PDF (English) PDF

Referências


World Health Organization. HIV/AIDS Department. WHO Three I´s Meeting: Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT) and TB Infection Control (IC) for people living with HIV. World Health Organization [Internet]. 2008 [cited 2018 Jan 9]. Available from: http://www.who.int/hiv/pub/meetingreports/WHO_3Is_meeting_report.pdf.

World Health Organization. Global tuberculosis report 2016. World Health Organization [Internet]. 2016 [cited 2018 Jan 9]. Available from: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.

Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico: Detectar, tratar e curar: desafios e estratégias brasileiras frente à tuberculose [Internet]. Brasília, Ministério da Saúde; 2015 [cited 2018 Jan 9];46(9):1-19. Available from: http://portalarquivos.saude.gov.br/images/pdf/2015/marco/25/Boletim-tuberculose-2015.pdf.

World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization [Internet]. 2011 [cited 2018 Jan 9]. Available from: http://apps.who.int/iris/bitstream/10665/44472/1/9789241500708_eng.pdf

Cattamanchi AS, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon–gamma release assays for the diagnosis of latent tuberculosis in HIV-infected individuals: A systematic review and meta-analysis. J Acquir Immune Defic Syndr [Internet]. 2011 [cited 2018 Jan 9];56(3):230-8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383328/pdf/nihms265921.pdf.

Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Syst Rev [Internet]. 2010 [cited 2018 Jan 9];1. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000171.pub3/epdf.

Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep [Internet]. 2009 [cited 2018 Jan 10];58:1–207. quiz CE1–4. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm

Centers for Disease Control. Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, TB Prevention. Latent Tuberculosis infection: a guide for primary health care providers [Internet]. 2013 [cited 2018 Jan 10]. Available from: https://www.cdc.gov/tb/publications/ltbi/pdf/targetedltbi.pdf.

European Centre for Disease Prevention and Control. WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2016. Stockholm: European Centre for Disease Prevention and Control. World Health Organization [Internet]. 2016 [cited 2018 Jan 10]. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/ecdc-tuberculosis-surveillance-monitoring-Europe-2016.pdf.

Canada Communicable Disease Report. Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection—2010 Update. Canada Communicable Disease Report, An Advisory Committee Statement (ACS) and Canadian Tuberculosis Committee (CTC) [Internet]. 2010 [cited 2018 Jan 10];36(5):[about 5 p].. Available from: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2010-36/canada-communicable-disease-report-10.html.

Trajman A, Steffen RE, Menzies D. Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: Na Overview of the Evidence. Pulm Med [Internet]. 2013 [cited 2018 Jan 10];2013:601737. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582085/pdf/PM2013-601737.pdf

Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Tratamento diretamente observado (TDO) da tuberculose na atenção básica: protocolo de enfermagem [Internet]. Brasília: Ministério da Saúde. 2011 [cited 2018 Jan 10]. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/tratamento_diretamente_observado_tuberculose.pdf

Souza JMO, Evangelista MSN, Trajman A. Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS. Biomed Res Int [Internet]. 2014; [cited 2018 Jan 9];2014:294963. Available from: http://dx.doi.org/10.1155/2014/294963.

Kussen GMB, Libera MD-C, Rossonid A, Rabonia SM. Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil. Braz J Infec Dis [Internet]. 2016 [cited 2018 Jan 9];20(1):69–75. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26706018

Souza MT, Silva MD, Carvalho R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo) [Internet]. 2010 [cited 2018 Jan 9];8(1 Pt 1):102-106. Available from: http://www.scielo.br/pdf/eins/v8n1/1679-4508-eins-8-1-0102.pdf

Pompeo DA, Rossi LA, Galvão CM. Integrative literature review: the initial step in the validation process of nursing diagnoses. Acta Paul Enferm [Internet]. 2009 [cited 2018 Jan 9];22(4):434-438. Available from: http://www.scielo.br/pdf/ape/v22n4/en_a14v22n4.pdf

Mendes KDSM, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto Enferm [Internet]. 2008 [cited 2018 Jan 12];14(4):758-64. Available from: http://www.scielo.br/pdf/tce/v17n4/18.pdf

Semu M, Fenta TG, Medhin G, Assefa D. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/ AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study. BMC Infect Dis [Internet]. 2017 [cited 2018 Jan 12];17:5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209939/pdf/12879_2016_Article_2109.pdf

Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, Durovni B, Chaisson RE. Long-term protection from isoniazid preventive therapy fortuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis [Internet]. 2015 [cited 2018 Jan 12];60(4):639-45. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209939/

Sumner T, Houben RM, Rangaka MX, Maartens G, Boulle A, Wilkinson RJ, et al. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. AIDS [Internet]. 2016 [cited 2018 Jan 12];30(8):1279-86. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26950316

Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2011 [cited 2018 Jan 14];377(9777):1588-98. Available from: http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(11)60204-3.pdf

Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis [Internet]. 2012 Jan [cited 2018 Jan 14];12(1):45-55. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568693/pdf/emss-47963.pdf

Centers for Disease Control and Prevention. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010. MMWR Recomm Rep [Internet]. 2010 [cited 2018 Jan 14]; 59(RR-5):1-25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20577159

Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiol Spectr [Internet]. 2017 [cited 2018 Jan 124];5(1). Available from: https://www.ncbi.nlm.nih.gov/pubmed/28233512

Doyle JS, Bissessor M, Denholm JT, Ryan N, Fairley CK, Leslie DE. Latent Tuberculosis screening using interferon-gamma release assays in an Australian HIV-infected cohort: is routine testing worthwhile? J Acquir Immune Defic Syndr [Internet]. 2014 [cited 2018 Jan 14];66(1):48-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24457631

Kim YJ, Kim SI, Kim YR, Wie SH, Park YJ, Kang MW. Predictive value ofinterferon-γ ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area. AIDS Res Hum Retroviruses [Internet]. 2012 [cited 2018 Jan 14];28(9):1038-43. Available from: http://online.liebertpub.com/doi/pdf/10.1089/aid.2011.0360.

Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis [Internet]. 2009 [cited 2018 Jan 14];48(7):954-62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19245343

Van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med [Internet]. 2009 [cited 2018 Jan 18];180(1):49-58. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19342414

Pullar ND, Steinum H, Brunn JN, Riise AMD. HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 years follow-up; a Norwegian prospective multicenter study. BMC Infect Dis [Internet].2014 [cited 2018 Jan 18];14:667. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273430/

Tagmouti S, Slater M, Benedetti A, Kik SV, Banaei N, Cattamanchi A, et al. Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review. Ann Am Thorac Soc [Internet]. 2014 [cited 2018 Jan 18];11(8):1267-76. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469356/

Banaei N, Gaur RL, Pai M. Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability? J Clin Microbiol [Internet]. 2016 [cited 2018 Jan 18];54(4):845-50. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809912/pdf/zjm845.pdf

Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev [Internet]. 2014 [cited 2018 Jan 18];27(1):3-20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910908/

Danel C, Kabran M, Inwoley A, Badje A, Herrmann JL, Moh R, et al. Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa. PLoS One [Internet]. 2014 [cited 2018 Jan 20];9(10):e107245. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199568/pdf/pone.0107245.pdf




DOI: https://doi.org/10.5205/1981-8963-v12i9a236490p2451-2458-2018



Licença Creative Commons
Esta obra está licenciada sob uma licença Creative Commons Atribuição 4.0 Internacional.

 

INDEXADORES E BASES BIBLIOGRÁFICAS:

 doajPeriódicoscapes

bvs elsevier nlm diadorim periodicaabec

 

cinahl citefactor cuidenplusb socolar ulrichs sumarios